Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kedaling tablets for depression in adults with coronary artery disease history
ChiCTR2500100128Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Apr 2025
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Kedaling in major depressive disorder (MDD) and Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Hamilton Depression Scale scores at 8 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Kedaling
03
Conditions
major depressive disorder (MDD)Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on ChiCTR2500100128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100128.